All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000623-16 | A retrospective study to compare the 3-year antiviral efficacy of nevirapine and efavirenz in combination with D4T and 3TC in 2NN patients | 2005-12-15 | due-trials |
| Reported results | 2004-001100-12 | A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week tre... | 2005-03-18 | due-trials |
| Reported results | 2004-001317-34 | A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule... | 2006-06-09 | due-trials |
| Reported results | 2004-001988-21 | A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap... | 2006-08-17 | due-trials |
| Reported results | 2004-002143-27 | A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL)... | 2005-12-17 | due-trials |
| Reported results | 2004-002166-38 | A 12-week randomised, double blind, placebo controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18µg q.d. in patients with CIOD and a concomitant diagnosis of ast... | 2006-10-27 | due-trials |
| Reported results | 2004-002241-12 | Ensayo clínico de fase IIIb - IV, aleatorizado y abierto, para evaluar la eficacia y seguridad de tenecteplasa junto con heparina no fraccionada administrada previo a la realización de PCI primaria, e... | 2006-04-22 | due-trials |
| Reported results | 2004-003742-18 | A ten-week, randomized, double-blind study evaluating the efficacy of Duloxetine 60 mg once daily versus placebo in outpatients with major depressive disorder and pain (EU-Pain enriched study) | 2006-05-02 | due-trials |
| Reported results | 2004-003986-34 | A randomised, double-blind, placebo-controlled, parallel group, 16-week MICARDIS (160 mg) tablets, proof-of-concept study, evaluating insulin sensitivity in overweight or obese, non-diabetic, normot... | 2005-10-14 | due-trials |
| Reported results | 2004-004590-28 | Efficacy and safety of 40 mg, 80 mg and 160 mg KUC 7483 BS administered twice daily and 160 mg administered once a day over 8 weeks in patients with overactive bladder syndrome (a double-blind, placeb... | 2005-06-30 | due-trials |
| Reported results | 2004-005238-37 | A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (25 µg salmeterol), administered a... | 2006-02-16 | due-trials |
| Reported results | 2005-000175-17 | A pharmacokinetic study to assess Nevirapine levels in HIV-infected patients with impaired hepatic function. | 2006-06-01 | due-trials |
| Reported results | 2005-000317-35 | A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-smal... | 2007-01-02 | due-trials |
| Completed, but no date, and reported results | 2005-000650-79 | A Randomized, Multiple-dose, Double-Blind, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Study to determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat Inhaler in Pa... | bad-data | |
| Reported results | 2005-000841-12 | A randomised open label, six way, cross-over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat(R) inhaler vs a Metered Dose Inhaler... | 2005-12-07 | due-trials |
| Reported results | 2005-000918-13 | A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (12.5 µg, 25 µg and 50 µg salmeter... | 2006-02-07 | due-trials |
| Reported results | 2005-001021-28 | .A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 w... | 2007-01-11 | due-trials |
| Reported results | 2005-001372-12 | An open-label, non-randomized, single arm study, to investigate the mechanism(s) by which nevirapine increases plasma high density lipoproteins concentration in HIV + subjects treated with Viramune ta... | 2007-11-23 | due-trials |
| Reported results | 2005-001866-15 | A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (... | 2008-09-26 | due-trials |
| Reported results | 2005-001998-10 | A phase III, randomized, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens (75mg day 1 followed by 150 mg day 2-completion, an... | 2006-06-26 | due-trials |
| Reported results | 2005-001999-12 | 'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s... | 2009-07-21 | due-trials |
| Reported results | 2005-002427-14 | A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment with BIBF 1120 Following Chemotherapy in Patients with Relapsed Ovarian Cancer | 2008-11-12 | due-trials |
| Reported results | 2005-002442-19 | A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ... | 2006-08-03 | due-trials |
| Reported results | 2005-002536-94 | 'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0... | 2011-08-19 | due-trials |
| Reported results | 2005-002851-41 | Reduced factorial design, randomized, double blind trial comparing combinations of telmisartan 20 or 80 mg and simvastatin 20 or 40 mg with single component therapies in the treatment of hypertension ... | 2007-08-10 | due-trials |
| Reported results | 2005-003000-11 | An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o... | 2007-01-30 | due-trials |
| Reported results | 2005-003176-38 | A placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4 hours 30 minutes after stroke onset | 2008-02-11 | due-trials |
| Reported results | 2005-003771-20 | A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffer... | 2006-10-18 | due-trials |
| Reported results | 2005-003788-22 | A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable... | 2008-07-11 | due-trials |
| Reported results | 2005-003894-26 | Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie... | 2009-04-01 | due-trials |
| Reported results | 2005-004005-28 | An open, randomised clinical Phase II trial to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536 in comparison to 50 mg of i.v. BI 2536 administered on d... | 2008-03-25 | due-trials |
| Reported results | 2005-004321-26 | A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 weeks of Nevira... | 2008-09-18 | due-trials |
| Reported results | 2005-004330-40 | - Ensayo clínico abierto y randomizado, para comparar la seguridad y eficacia virológica de Atazanavir/ritonavir versus Nevirapina con un régimen de base que incluya Tenofovir y Emtricitabina, en ... | 2011-02-08 | due-trials |
| Reported results | 2005-004597-24 | A randomised, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory study comparing BI 1356 BS (1mg, 5mg and 10mg) to open label glimepiride each administered orally o... | 2007-08-21 | due-trials |
| Reported results | 2005-004698-39 | Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily) i... | 2007-09-12 | due-trials |
| Reported results | 2005-004949-34 | A randomized, double-blind, placebo-controlled, parallel-group clinical trial to examine the efficacy and safety of early pramipexole treatment versus delayed pramipexole treatment in patients with ne... | 2009-04-22 | due-trials |
| Reported results | 2005-005023-33 | Ensayo para evaluar la seguridad y eficacia de Tipranavir (TPV) potenciado con dosis bajas de ritonavir (TPV/r) 500 mg/200 mg dos veces al día en pacientes VIH-positivos co-infectados con VCH o VBH,... | 2008-10-08 | due-trials |
| Reported results | 2005-005225-54 | A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole Sifrol, Mirapexin 0.125-0.75 mg/day per os for 12 weeks to investigate the effects on RLS symptoms IRL... | 2007-07-04 | due-trials |
| Reported results | 2005-005249-21 | A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer | 2008-12-19 | due-trials |
| Reported results | 2005-005253-22 | An open, randomised, clinical phase II trial in patients with unresectable advanced pancreatic cancer investigating the efficacy, safety, and pharmacokinetics of BI 2536 administered in repeated 3-wee... | 2008-11-24 | due-trials |
| Reported results | 2005-005255-18 | A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic ho... | 2008-02-14 | due-trials |
| Reported results | 2005-005264-86 | Ensayo para evaluar la seguridad, eficacia y farmacocinética de TipRanavir potenciado con dosis bajas de ritonavir (TPV/r) 500 mg/200 mg dos veces al día en una población VIH-positiva con diversidad ... | 2008-10-20 | due-trials |
| Reported results | 2005-005368-10 | A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg admi... | 2008-06-09 | due-trials |
| Reported results | 2005-005615-21 | A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Tiotr... | 2008-02-20 | due-trials |
| Reported results | 2005-005616-25 | A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de... | 2008-10-13 | due-trials |
| Reported results | 2005-005985-35 | A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 an... | 2007-02-09 | due-trials |
| Reported results | 2005-006128-13 | A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole Sifrol, Mirapexin orally for 12 weeks to investigate the safety and efficacy in out-p... | 2007-06-23 | due-trials |
| Exempt, with results | 2006-000613-38 | An open, randomised clinical Phase I/IIa trial to investigate the maximum tolerated dose, efficacy, safety and pharmacokinetics of repeated three-week courses of a single dose i.v. BI 2536 on day 1 in... | 2009-10-27 | not-yet-due |
| Reported results | 2006-000822-30 | A randomized, double-blind, double-dummy, parallel group trial comparing 12 weeks treatment with tiotropium inhalation capsules 18 mcg via the HandiHaler® once daily to Combivent® Inhalation Aerosol C... | 2007-11-19 | due-trials |
| Reported results | 2006-001009-27 | A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th... | 2009-02-06 | due-trials |
| Reported results | 2006-001618-34 | An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression | 2008-08-26 | due-trials |
| Reported results | 2006-001975-40 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 15 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on epit... | 2008-07-09 | due-trials |
| Reported results | 2006-002018-36 | An open label phase II trial to assess the efficacy and safety of a once daily oral dose of 50 mg BIBW 2992 in two cohorts of patients with HER2-negative metastatic breast cancer after failure of no... | 2009-06-16 | due-trials |
| Reported results | 2006-002311-27 | A randomized, double-blind, placebo-controlled, five parallel group study investigating the efficacy and safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg administered orally once daily) over 12 weeks i... | 2007-09-28 | due-trials |
| Reported results | 2006-002694-52 | A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety an... | 2008-04-04 | due-trials |
| Reported results | 2006-002814-37 | A phase II study of BIBW 2992 added to letrozole in patients with estrogen receptor positive hormone refractory metastatic breast cancer progressing on letrozole | 2010-01-04 | due-trials |
| Reported results | 2006-002875-42 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci... | 2011-04-01 | due-trials |
| Reported results | 2006-003048-52 | A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of Tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bladde... | 2009-02-15 | due-trials |
| Ongoing | 2006-003385-34 | The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma. | not-yet-due | |
| Reported results | 2006-004086-33 | Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on stat... | 2009-05-26 | due-trials |
| Reported results | 2006-004423-11 | An uncontrolled, open-label, titration, long-term safety up to 12 months and efficacy study of tamsulosin hydrochloride in children with neuropathic bladder, with a randomized pharmacokinetic sub-... | 2009-06-12 | due-trials |
| Reported results | 2006-004528-35 | A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992... | 2007-06-18 | due-trials |
| Reported results | 2006-004529-27 | Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC... | 2009-02-09 | due-trials |
| Reported results | 2006-004610-41 | A randomised, double-blind, placebo-controlled two-year trial to examine the change in Exercise Endurance and COPD in Patients Treated with Tiotropium (Spiriva (R)) 18 µg once daily (EXACCT trial) | 2010-06-30 | due-trials |
| Reported results | 2006-004828-36 | Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Delivere... | 2008-01-14 | due-trials |
| Reported results | 2006-004829-29 | Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2 µg, 5 µg, 10 µ... | 2008-10-03 | due-trials |
| Reported results | 2006-004870-28 | Prospective, randomized, national, multi-centre, open-label, blinded endpoint study to compare Aggrenox® b.i.d. (200 mg dipyridamole MR + 25 mg acetylsalicylic acid) when started within 24 hours of st... | 2009-02-05 | due-trials |
| Reported results | 2006-005256-33 | A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-s... | 2008-05-16 | due-trials |
| Reported results | 2006-006276-38 | A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus P... | 2010-07-02 | due-trials |
| Reported results | 2006-006431-42 | A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi... | 2008-08-28 | due-trials |
| Reported results | 2007-000032-68 | A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv... | 2009-03-20 | due-trials |
| Reported results | 2007-000073-39 | A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm... | 2008-11-25 | due-trials |
| Reported results | 2007-000074-23 | A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm... | 2008-12-18 | due-trials |
| Reported results | 2007-000207-15 | A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalati... | 2009-06-30 | due-trials |
| Reported results | 2007-001219-44 | Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2... | 2012-09-07 | due-trials |
| Reported results | 2007-001840-33 | Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD patients (a randomised, double-blind, double-dummy, parallel group, on... | 2010-04-01 | due-trials |
| Reported results | 2007-001946-42 | A multinational, randomised, double-blind, placebo. and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50µg, 100µg, 200µg) of BEA 2180 to tiotropium 5 µ... | 2009-05-05 | due-trials |
| Reported results | 2007-001991-34 | A randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with bisacodyl (Dulcolax®) tablets 10 mg administered orally, once daily, in... | 2009-06-02 | due-trials |
| Reported results | 2007-002087-10 | A randomised, double -blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops 10 mg administered o... | 2009-01-07 | due-trials |
| Reported results | 2007-002409-36 | An eight-week randomised, 4-arm, double-blind study to compare the efficacy and safety of combinations of telmisartan 40mg + amlodipine 5mg versus telmisartan 80mg + amlodipine 5mg versus amlodipine 5... | 2008-10-14 | due-trials |
| Reported results | 2007-002410-19 | An open label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 5mg or the combination of telmisartan 80mg + amlodipine 5mg table... | 2009-04-09 | due-trials |
| Reported results | 2007-002421-68 | An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi... | 2009-02-09 | due-trials |
| Reported results | 2007-002422-29 | An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ... | 2009-09-16 | due-trials |
| Reported results | 2007-002448-10 | A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks w... | 2009-06-17 | due-trials |
| Reported results | 2007-002450-28 | A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient gly... | 2009-05-21 | due-trials |
| Reported results | 2007-002456-41 | A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally once d... | 2010-01-22 | due-trials |
| Reported results | 2007-002457-24 | A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient gly... | 2009-07-16 | due-trials |
| Reported results | 2007-002522-29 | A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona... | 2013-07-03 | due-trials |
| Reported results | 2007-002586-12 | Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm... | 2011-12-31 | due-trials |
| Reported results | 2007-002630-11 | A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220... | 2009-11-16 | due-trials |
| Reported results | 2007-002631-86 | A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto... | 2011-05-05 | due-trials |
| Reported results | 2007-003169-42 | A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd, M... | 2008-09-30 | due-trials |
| Reported results | 2007-003353-90 | A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipe... | 2008-05-22 | due-trials |
| Reported results | 2007-003654-29 | A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne... | 2011-11-24 | due-trials |
| Reported results | 2007-003742-15 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of four weeks treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (inhalation po... | 2008-09-16 | due-trials |
| Reported results | 2007-004076-38 | A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder | 2009-11-06 | due-trials |
| Reported results | 2007-004234-16 | Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD). | 2010-07-23 | due-trials |
| Reported results | 2007-004235-37 | Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinsons disease (PD). | 2010-08-02 | due-trials |
| Reported results | 2007-004301-99 | Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc... | 2009-10-28 | due-trials |
| Reported results | 2007-004328-18 | A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg admi... | 2008-06-09 | due-trials |
| Reported results | 2007-004585-40 | A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea... | 2010-12-21 | due-trials |
| Reported results | 2007-004803-36 | Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in p... | 2017-11-13 | due-trials |
| Reported results | 2007-004805-80 | Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast cancer after failure of trastuzumab therapy | 2009-08-28 | due-trials |
| Reported results | 2007-005087-26 | Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg Tio... | 2009-02-10 | due-trials |
| Reported results | 2007-005107-17 | A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), doubleblind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter... | 2008-11-21 | due-trials |
| Reported results | 2007-005134-36 | A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), doubleblind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala... | 2008-11-21 | due-trials |
| Reported results | 2007-005135-28 | A randomised, double–blind, crossover efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/ 25 µg) Inhalation Powder in the morning (PE Capsule via tiotropium/salmeterol HandiHaler®), Tiotr... | 2009-08-26 | due-trials |
| Exempt, with results | 2007-005684-10 | An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myelo... | 2010-03-30 | not-yet-due |
| Reported results | 2007-005983-28 | Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ... | 2013-10-05 | due-trials |
| Reported results | 2007-007536-25 | Randomized, Open-label study of Dabigatran Etexilate, a Novel, oral, Direct Thrombin-inhibitor in clinical development, in Elective Percutaneous Coronary Intervention. (D-Fine) | 2010-08-07 | due-trials |
| Reported results | 2007-007865-19 | A 4-week, randomized, double blind, double dummy, placebo controlled, parallel group study comparing the influence of BI 1356 (5 mg) and sitagliptin (100 mg) administered orally once daily on various ... | 2008-11-19 | due-trials |
| Reported results | 2008-000079-31 | A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ... | 2009-07-06 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-000342-32 | An open-label, flexible dose, follow-up study to evaluate safety and efficacy of oral pramipexole (0.0625-0.5 mg/day) for 24 weeks in children and adolescents (age 6-17 years) diagnosed with Tourette ... | 2009-08-14 | bad-data |
| Reported results | 2008-000343-33 | A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investigate... | 2009-08-07 | due-trials |
| Reported results | 2008-000562-23 | Randomised, Double-Blind, Cross-over Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 2 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination (FDC) with 5μg T... | 2009-02-20 | due-trials |
| Reported results | 2008-000640-14 | A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, as m... | 2009-10-06 | due-trials |
| Reported results | 2008-000641-54 | A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind to p... | 2009-10-31 | due-trials |
| Reported results | 2008-000750-13 | A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients. | 2011-02-11 | due-trials |
| Reported results | 2008-000873-40 | Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg o comprimidos de Telmisartán 80 mg como terapia... | 2009-12-11 | due-trials |
| Reported results | 2008-000874-19 | A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg ov... | 2010-06-30 | due-trials |
| Reported results | 2008-001156-43 | A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail... | 2010-04-02 | due-trials |
| Reported results | 2008-001264-37 | A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients | 2013-07-04 | due-trials |
| Reported results | 2008-001413-14 | A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 wee... | 2011-07-25 | due-trials |
| Reported results | 2008-001414-25 | A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (5 mcg/day) over 48 week... | 2011-07-25 | due-trials |
| Reported results | 2008-001546-67 | A Phase II single-arm trial of BIBW 2992 in demographically and genotypically selected non-small cell lung cancer patients | 2012-06-19 | due-trials |
| Reported results | 2008-001640-40 | A phase III randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and safety of twice daily administration of the free combination of BI 1356 2.5 mg + metformin 500... | 2010-06-25 | due-trials |
| Reported results | 2008-001933-84 | A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation... | 2010-12-02 | due-trials |
| Reported results | 2008-001934-28 | A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation... | 2010-12-08 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2008-002072-10 | Multicenter, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in... | 2015-12-30 | bad-data |
| Reported results | 2008-002731-32 | A 12 weeks open label two parallel groups study to assess the efficacy of orally administered duloxetine 60 mg and 120 mg per day on treatment outcomes in patients with diabetic peripheral neuropatic ... | 2010-06-23 | due-trials |
| Reported results | 2008-003118-86 | A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 18 weeks in Type 2 diabetic patients with insufficient gly... | 2010-01-14 | due-trials |
| Reported results | 2008-003538-11 | Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl... | 2011-11-28 | due-trials |
| Exempt, with results | 2008-003617-27 | An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in pat... | 2021-04-23 | not-yet-due |
| Reported results | 2008-003647-36 | Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2actuations of 2.5 µg] and 1... | 2010-09-21 | due-trials |
| Reported results | 2008-003704-67 | Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2actuations of 2.5 µg] and 1... | 2010-09-27 | due-trials |
| Reported results | 2008-003932-40 | A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 720mg/day orally, in male and female patients sufferi... | 2009-11-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-004460-39 | A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-... | 2009-06-23 | bad-data |
| Reported results | 2008-004681-55 | An open label, phase IIIb, randomized parallel group study to assess the efficacy and safety of switching HIV-1 infected patients successfully treated with a Nevirapine IR based regimen to Nevirapine ... | 2012-01-10 | due-trials |
| Reported results | 2008-005248-17 | RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge... | 2013-03-04 | due-trials |
| Exempt, with results | 2008-005364-14 | A phase I-II study of BIBF 1120 and Folfox compared to Bevacizumab and Folfox in first line metastatic colorectal cancer patients. | 2013-07-18 | not-yet-due |
| Reported results | 2008-005615-18 | LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activa... | 2017-03-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-005855-61 | An open-label, multiple dose, cross-over study to evaluate the steady-state pharmacokinetic parameters of nevirapine extended release tablets in HIV-1 infected children, with an optional extension pha... | 2012-09-10 | bad-data |
| Reported results | 2008-006288-36 | Phase II open label trial to assess the efficacy and the impact on QTcF of continuous oral BIBW 2992 at a daily dose of 50 mg in patients with relapsed or refractory solid tumours including patients w... | 2011-04-27 | due-trials |
| Reported results | 2008-006334-10 | Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 µg [2 actuations ... | 2009-07-20 | due-trials |
| Reported results | 2008-006625-14 | Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, delivered with the Respimat® Inhaler, after 3 Weeks of Olodaterol Once Daily... | 2011-12-19 | due-trials |
| Reported results | 2008-006831-10 | Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c... | 2016-09-26 | due-trials |
| Trial is outside EEC, and reported results | 2008-006866-27 | Open-label safety and tolerability study of dabigatran etexilate given for 3 days at the end of standard anticoagulant therapy in children aged 12 years to less than 18 years | bad-data | |
| Reported results | 2008-007097-38 | A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-contai... | 2013-07-26 | due-trials |
| Reported results | 2008-007711-32 | A randomised, double-blind, double dummy, active controlled, parallel group, forced titration study to compare the fixed-dose combination of Telmisartan 80mg plus Hydrochlorothiazide 25mg (T80/HCTZ25)... | 2010-04-23 | due-trials |
| Reported results | 2008-007938-21 | A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients | 2011-06-16 | due-trials |
| Reported results | 2008-008127-15 | A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with piog... | 2013-02-11 | due-trials |
| Reported results | 2008-008296-33 | A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie... | 2011-10-20 | due-trials |
| Reported results | 2008-008494-59 | A phase III randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 m... | 2011-06-16 | due-trials |
| Reported results | 2009-009516-44 | A randomised, open label, parallel group Phase II study comparing the efficacy and tolerability of BIBF 1120 versus sunitinib in previously untreated patients with Renal Cell Cancer. | 2020-06-19 | due-trials |
| Reported results | 2009-010668-40 | A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 microgram... | 2013-12-26 | due-trials |
| Reported results | 2009-010669-22 | A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ... | 2013-12-09 | due-trials |
| Exempt, with results | 2009-011925-14 | A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients. | 2016-10-12 | not-yet-due |
| Reported results | 2009-011996-59 | An open label, partially randomised Phase II trial to investigate the efficacy and safety of BIBW 2992 in patients with metastatic colorectal cancer who never received prior anti-EGFR treatment | 2012-03-29 | due-trials |
| Reported results | 2009-012579-90 | Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and ri... | 2011-04-11 | due-trials |
| Reported results | 2009-013157-15 | A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca... | 2018-08-21 | due-trials |
| Reported results | 2009-013269-24 | Randomised, double-blind, triple dummy, partial cross-over (each active treatment with placebo) study using an Environmental Challenge Chamber (ECC) to assess the safety and efficacy of 2 weeks of ora... | 2010-04-22 | due-trials |
| Reported results | 2009-013289-20 | A Phase III, randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin 5 mg administered orally once daily over 24 weeks in type 2 diabetic patients with ins... | 2012-05-14 | due-trials |
| Reported results | 2009-013395-48 | A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalation ... | 2011-02-17 | due-trials |
| Reported results | 2009-013549-27 | A randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to ... | 2010-09-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-013618-29 | Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y... | 2016-02-18 | bad-data |
| Reported results | 2009-013668-38 | A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic pati... | 2012-05-09 | due-trials |
| Reported results | 2009-013788-21 | A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | 2016-09-26 | due-trials |
| Reported results | 2009-014395-21 | Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of... | 2011-04-27 | due-trials |
| Reported results | 2009-014416-35 | Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5µg] and 10 µg [2 actuations of... | 2011-04-05 | due-trials |
| Reported results | 2009-014417-27 | Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat... | 2011-01-04 | due-trials |
| Reported results | 2009-014418-86 | Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat... | 2011-01-10 | due-trials |
| Reported results | 2009-014551-80 | Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placebo in ... | 2011-08-09 | due-trials |
| Reported results | 2009-014563-39 | Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29... | 2016-01-07 | due-trials |
| Reported results | 2009-014880-38 | A randomised, double-blind, 8 treatments, 4 periods, incomplete crossover study to determine the optimal free dose combination of BI 1744 CL and tiotropium bromide (both delivered by the Respimat® Inh... | 2011-02-03 | due-trials |
| Reported results | 2009-015255-25 | A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally once daily over 24 weeks in type 2 diabetic patients (age... | 2011-07-21 | due-trials |
| Reported results | 2009-015476-98 | LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio... | 2018-07-26 | due-trials |
| Reported results | 2009-015713-51 | A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut... | 2013-06-22 | due-trials |
| Reported results | 2009-015770-35 | Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotox... | 2014-06-04 | due-trials |
| Exempt, with results | 2009-015911-42 | A phase Ib open label clinical trial of continuous once daily oral treatment using BIBW 2992 plus cetuximab (Erbitux®) in patients with non-small cell lung cancer with progression following prior erlo... | not-yet-due | |
| Reported results | 2009-016154-40 | A randomised, double-blind, placebo-controlled parallel group efficacy and safety trial of BI 10773 (10 and 25 mg administered orally once daily) over 24 weeks in patients with type 2 diabetes mellitu... | 2012-05-24 | due-trials |
| Reported results | 2009-016178-33 | A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ... | 2015-09-22 | due-trials |
| Reported results | 2009-016179-31 | A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therap... | 2012-08-28 | due-trials |
| Reported results | 2009-016243-20 | A phase III randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 10773 and sitagliptin administered orally over 24 weeks, in drug naïve patients with type 2 diab... | 2012-03-19 | due-trials |
| Reported results | 2009-016244-39 | A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per... | 2015-08-28 | due-trials |
| Reported results | 2009-016251-21 | A multicentre, randomised, placebo- and active-controlled, 5-way crossover trial to characterise the pharmacokinetics and evaluate the bronchodilator efficacy and safety of once-daily tiotropium deliv... | 2011-11-16 | due-trials |
| Reported results | 2009-016258-41 | A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with typ 2 dia... | 2012-02-03 | due-trials |
| Reported results | 2009-016971-31 | A phase III, randomised, double-blind, placebo-controlled parallel group safety and efficacy study of linagliptin (5 mg administered orally once daily) over 12 weeks followed by a 40 week double-blind... | 2012-07-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-017004-91 | A randomised, double-blind, placebo-controlled parallel group dose finding study of linagliptin (1 mg or 5 mg administered orally once daily) over 12 weeks in children and adolescents, from 10 to 17 ... | 2016-02-11 | bad-data |
| Reported results | 2009-017336-40 | Prospective, open label TElmisartan/AMlodipine single pill STudy to Assess the efficacy in patients with essential hypertension who are not controlled on RAASi mono-therapy being switched | 2011-07-07 | due-trials |
| Ongoing | 2009-017661-34 | An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat... | not-yet-due | |
| Reported results | 2009-017745-55 | A Phase II randomised, double-blind, placebo-controlled, incomplete crossover trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25μg, 2.... | 2011-05-23 | due-trials |
| Reported results | 2009-018004-18 | A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once dail... | 2012-11-13 | due-trials |
| Reported results | 2009-018005-43 | A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once dai... | 2012-11-07 | due-trials |
| Reported results | 2009-018006-21 | A Phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered twic... | 2011-08-19 | due-trials |
| Reported results | 2009-018197-66 | Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par... | 2014-10-30 | due-trials |
| Reported results | 2010-018471-26 | A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5.0 μ... | 2012-01-09 | due-trials |
| Reported results | 2010-018708-99 | An open-label, phase II study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagl... | 2013-07-08 | due-trials |
| Reported results | 2010-018723-26 | An open label, non-comparative, pharmacokinetic and pharmacodynamic study to evaluate the effect of Dabigatran Etexilate on coagulation parameters including a calibrated thrombin time test in patients... | 2013-05-22 | due-trials |
| Reported results | 2010-019707-32 | LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology. | 2017-06-19 | due-trials |
| Reported results | 2010-019802-17 | A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ... | 2012-03-07 | due-trials |
| Reported results | 2010-019968-37 | A phase III, randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of BI 10773 (10 mg and 25 mg administered orally once daily) during 52 weeks in patients with type 2... | 2013-04-22 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-021093-11 | A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive... | 2013-12-27 | bad-data |
| Reported results | 2010-021375-92 | A 24-week phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of twice daily oral administration of empagliflozin + metformin compared with the individual comp... | 2014-12-01 | due-trials |
| Reported results | 2010-021415-16 | Randomised phase II study of afatinib alone or in combination with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastase... | 2014-08-26 | due-trials |
| Reported results | 2010-021715-17 | A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype... | 2014-05-15 | due-trials |
| Reported results | 2010-021716-42 | A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and rib... | 2014-03-12 | due-trials |
| Reported results | 2010-021734-59 | Safety and Efficacy of 120 mg and 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV... | 2014-06-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-021778-13 | A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (2.5 micrograms and 5 micrograms... | 2013-11-12 | bad-data |
| Reported results | 2010-021945-29 | LUX-Breast 2;An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant and/or adjuvant trea... | 2017-03-13 | due-trials |
| Reported results | 2010-022458-18 | A phase II randomised, double-blind, placebo-controlled incomplete cross-over trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 μg, 2... | 2012-10-29 | due-trials |
| Reported results | 2010-022685-27 | A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt | 2013-06-03 | due-trials |
| Reported results | 2010-022718-17 | A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (inc... | 2013-05-23 | due-trials |
| Reported results | 2010-023112-14 | A Phase III, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 µg and 5 µg once... | 2012-04-19 | due-trials |
| Ongoing, reported early | 2010-023167-17 | A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 22.7, 45.5, and 90.9 µg b.... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2010-023168-41 | A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 45.5, 90.9 and 181.8 μg b.... | 2011-12-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2010-023169-23 | A randomised, double-blind, double-dummy, active-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 90.9 181.8 and 363.6 μg b.i... | 2011-11-11 | bad-data |
| Completed, but no date, and reported results Terminated | 2010-023326-20 | A randomized, double blind, placebo and active controlled, parallel group study to evaluate the safety and efficacy of 6-week treatment with oral doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d... | bad-data | |
| Reported results | 2010-023499-25 | A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea... | 2011-09-30 | due-trials |
| Reported results | 2010-024251-87 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmo... | 2013-10-09 | due-trials |
| Reported results | 2010-024252-29 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fib... | 2013-11-18 | due-trials |
| Reported results | 2010-024454-10 | An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer | 2014-11-18 | due-trials |
| Reported results | 2011-000141-20 | A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C in... | 2014-06-24 | due-trials |
| Reported results | 2011-000347-25 | A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi... | 2012-07-31 | due-trials |
| Reported results | 2011-000383-10 | A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 m... | 2013-09-10 | due-trials |
| Reported results | 2011-000391-34 | A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ... | 2016-12-06 | due-trials |
| Reported results | 2011-000392-14 | A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w... | 2016-09-12 | due-trials |
| Reported results Terminated | 2011-000935-98 | A single dose, placebo-controlled, randomised, double-blind double dummy, 5-way crossover (7 treatments, 5 periods incomplete block), including 24-h pulmonary function tests, pharmacodynamic compariso... | 2011-11-11 | due-trials |
| Reported results | 2011-001758-26 | A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t... | 2015-12-08 | due-trials |
| Reported results | 2011-001777-43 | A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t... | 2015-05-18 | due-trials |
| Reported results Terminated | 2011-001801-29 | A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Tiotr... | 2011-11-11 | due-trials |
| Reported results | 2011-001814-33 | LUX-Lung 7: A randomised, open-label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung | 2019-04-12 | due-trials |
| Reported results | 2011-002276-16 | A randomised, double-blind, double dummy study investigating the efficacy and safety of Linagliptin co-administered with metformin QD at evening time versus metformin bid over 14 weeks in treament nai... | 2013-03-05 | due-trials |
| Reported results | 2011-002285-21 | Evaluation of the long term safety of the use of dabigatran etexilate in patients with a bileaflet mechanical heart valve | 2013-06-07 | due-trials |
| Reported results | 2011-002380-24 | LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b... | 2017-12-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-002766-21 | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez... | 2021-02-01 | bad-data |
| Trial is outside EEC, and reported results | 2011-002774-23 | An open-label clinical study to investigate pharmacokinetics (PK) of different doses (0.125 mg, 0.25 mg, 0.5 mg) of pramipexole administered once daily orally in pediatric patients who are individuall... | bad-data | |
| Reported results | 2011-002894-48 | Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, activ... | 2016-10-28 | due-trials |
| Reported results | 2011-002908-33 | A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated fol... | 2014-09-09 | due-trials |
| Exempt, with results | 2011-003081-32 | An exploratory study to investigate the pharmacokinetics and effects of DABIgatran etexilate in patients with stable severe RENAL disease: DabiRenal Een studie naar de farmacokinetiek en effecten v... | not-yet-due | |
| Reported results | 2011-003890-27 | A multi-centre, double-blind, randomised, parallel group study to assess the efficacy and safety of multiple doses of topically applied hyperemisation-inducing ointment (2 cm ointment line per applica... | 2013-04-19 | due-trials |
| Reported results | 2011-004148-23 | A multicenter, international, randomized, parallel group, double blind,placebo-controlled CArdiovascular Safety & Renal Microvascular outcomE with LINAgliptin, 5 mg once daily in patients with type 2 ... | 2018-01-18 | due-trials |
| Completed, but no date, and reported results | 2011-004158-24 | A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, treatme... | bad-data | |
| Reported results | 2011-004253-11 | A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg)... | 2013-09-26 | due-trials |
| Reported results | 2011-004354-25 | A 28-day randomised, placebo-controlled, double-blind parallel group phase IIa trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of 2.5 mg, 10 mg... | 2014-04-20 | due-trials |
| Reported results | 2011-004659-37 | A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)... | 2013-11-20 | due-trials |
| Reported results | 2011-004660-30 | A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)... | 2013-11-26 | due-trials |
| Reported results | 2011-004710-42 | Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2... | 2013-08-12 | due-trials |
| Reported results | 2011-005512-28 | A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 µg and 5 µg) administered once daily in the af... | 2014-12-04 | due-trials |
| Reported results | 2012-000095-42 | A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies... | 2016-09-15 | due-trials |
| Reported results | 2012-000905-53 | A randomised, double blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 we... | 2013-12-03 | due-trials |
| Reported results | 2012-001873-10 | A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat® inhaler, after 4 weeks of once daily [5 µg in the evening ... | 2013-09-26 | due-trials |
| Reported results | 2012-002270-31 | A phase III, randomised, double-blind, parallel group, 24 week study to evaluate efficacy and safety of once daily empagliflozin 10 mg and 25 mg compared to placebo, all administered as oral fixed dos... | 2015-03-23 | due-trials |
| Reported results | 2012-002271-34 | A phase III, randomized, double-blind, parallel group study to evaluate the efficacy and safety of linagliptin 5 mg compared to placebo, administered as oral fixed dose combination with empagliflozin ... | 2015-03-13 | due-trials |
| Reported results | 2012-002487-27 | A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6... | 2021-05-28 | due-trials |
| Reported results | 2012-002603-17 | A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 m... | 2015-12-07 | due-trials |
| Reported results | 2012-002945-40 | Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial | 2016-10-18 | due-trials |
| Reported results | 2012-003533-41 | A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio... | 2015-03-11 | due-trials |
| Reported results | 2012-003534-17 | A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1b... | 2014-10-21 | due-trials |
| Reported results | 2012-003535-27 | A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu... | 2015-03-11 | due-trials |
| Exempt, with results | 2012-004090-16 | A randomised, double-blind, placebo-controlled trial for establishing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of multiple subcutaneous doses of BI 655064 in heal... | 2015-04-27 | not-yet-due |
| Reported results | 2012-004384-48 | A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-con... | 2015-07-31 | due-trials |
| Reported results | 2012-004544-30 | A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat... | 2019-01-14 | due-trials |
| Reported results | 2012-005201-48 | Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex... | 2018-08-28 | due-trials |
| Reported results | 2013-000808-41 | Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod... | 2015-03-20 | due-trials |
| Reported results | 2013-001110-15 | A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer | 2021-12-15 | due-trials |
| Reported results | 2013-001291-38 | Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 year... | 2017-01-31 | due-trials |
| Trial is partly outside EEC, and reported results | 2013-002114-12 | Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt... | 2019-11-20 | bad-data |
| Reported results | 2013-002243-29 | A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed ... | 2014-11-24 | due-trials |
| Reported results | 2013-002264-24 | A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium+ oldaterol fixed do... | 2015-01-13 | due-trials |
| Trial is partly outside EEC, and reported results | 2013-002304-14 | An open-label, randomised, multicentre, single-dose, parallel group trial to evaluate pharmacokinetics and pharmacodynamics of empagliflozin in children and adolescents from 10 to less than 18 years ... | 2016-02-29 | bad-data |
| Reported results | 2013-002622-23 | Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial | 2016-11-06 | due-trials |
| Reported results | 2013-002652-32 | A randomised, placebo-controlled, double-blind, single dose, cross-over study to evaluate the efficacy and safety of orally inhaled tiotropium + olodaterol as both a fixed dose combination and a free ... | 2014-06-06 | due-trials |
| Reported results | 2013-002671-18 | An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d... | 2015-10-31 | due-trials |
| Reported results | 2013-002902-29 | A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist ... | 2016-11-18 | due-trials |
| Reported results | 2013-003201-26 | A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl... | 2017-06-05 | due-trials |
| Reported results | 2013-003444-24 | Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls... | 2018-10-10 | due-trials |
| Reported results | 2013-003646-16 | A randomized, double-blind, placebo-controlled, parallel groups study to investigate the safety and tolerability, efficacy, pharmacokinetics and pharmacodynamics of three BI 187004 doses given once d... | 2015-08-02 | due-trials |
| Reported results | 2013-003666-13 | A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with a... | 2016-07-26 | due-trials |
| Exempt | 2013-004011-41 | A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following D... | not-yet-due | |
| Reported results Terminated | 2013-004567-30 | A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD) | 2015-04-15 | due-trials |
| Reported results | 2013-004813-41 | A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete... | 2016-10-20 | due-trials |
| Reported results | 2013-005015-28 | A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment period in ... | 2016-06-13 | due-trials |
| Reported results | 2013-005031-24 | A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t... | 2017-10-09 | due-trials |
| Reported results | 2013-005040-28 | A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t... | 2017-10-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-000583-18 | Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years | 2019-11-19 | bad-data |
| Reported results | 2014-000904-88 | A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ... | 2017-04-25 | due-trials |
| Reported results | 2014-001077-14 | An open label, single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbou... | 2017-06-13 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-001259-22 | open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 year o... | 2016-02-09 | bad-data |
| Completed, but no date, and reported results | 2014-001687-36 | An open label extension trial assessing the safety and and efficay of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis. Avoin jatkotutkimus, jossa ... | bad-data | |
| Reported results | 2014-001922-14 | A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w... | 2017-10-23 | due-trials |
| Exempt, with results | 2014-002123-10 | Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,... | 2020-08-05 | not-yet-due |
| Reported results | 2014-002161-30 | A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small... | 2018-11-16 | due-trials |
| Reported results | 2014-002275-28 | A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ... | 2017-03-29 | due-trials |
| Reported results | 2014-003890-40 | Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial) | 2016-11-14 | due-trials |
| Reported results | 2014-004544-36 | A Phase III, randomized, double-blind, multi-center, multi-national trial to evaluate efficacy and safety of BI 695500 versus rituximab as a first-line immunotherapy treatment in patients with low tum... | 2015-12-07 | due-trials |
| Reported results | 2014-004794-16 | An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) with... | 2018-05-11 | due-trials |
| Reported results | 2014-004932-20 | A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 week... | 2018-03-19 | due-trials |
| Reported results | 2014-004959-30 | A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with in... | 2016-10-10 | due-trials |
| Reported results | 2014-005102-38 | BI 655066 / ABBV-066 (risankizumab) versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with r... | 2018-10-25 | due-trials |
| Reported results | 2014-005117-23 | BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1) BI 65506... | 2017-09-18 | due-trials |
| Reported results | 2014-005256-26 | A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w... | 2017-12-28 | due-trials |
| Reported results | 2015-000392-28 | A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ... | 2018-11-28 | due-trials |
| Reported results | 2015-000404-25 | A randomized, controlled multi-centre parallel group study to assess the efficacy and safety of multiple doses of a topically applied combination containing diclofenac 2% + capsaicin 0.075% (2 g formu... | 2017-07-21 | due-trials |
| Reported results | 2015-000640-42 | A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment wit... | 2017-01-31 | due-trials |
| Exempt, with results | 2015-001111-12 | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit | 2021-11-23 | not-yet-due |
| Exempt, with results | 2015-001477-41 | A randomised, double blind phase I/II trial to investigate efficacy, immunogenicity and safety of intradermally administered BI 1361849 (CV9202) plus afatinib versus placebo plus afatinib as first-lin... | 2016-06-20 | not-yet-due |
| Reported results | 2015-001750-15 | A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active... | 2020-08-18 | due-trials |
| Reported results | 2015-001834-15 | An open label, single group, long term safety extension trial of BI 655066, in patients with moderately to severely active Crohn's disease | 2019-06-19 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-002177-37 | Single dose, open label, uncontrolled, safety trial of intravenous administration of idarucizumab to paediatric patients enrolled from ongoing phase IIb/III clinical trials with dabigatran etexilate f... | 2019-10-19 | bad-data |
| Reported results | 2015-002619-14 | A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in pa... | 2018-04-13 | due-trials |
| Reported results | 2015-002634-41 | Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis (RA): an open-label extension trial for patients who have completed tri... | 2017-11-01 | due-trials |
| Exempt, with results | 2015-002892-30 | An open-label, Phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine in patients with acute myeloid... | 2023-01-16 | not-yet-due |
| Reported results | 2015-002974-20 | A randomised, double-blind, cross-over study to evaluate the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (5/5 µg) compared with tiotropium (5 µg), bo... | 2017-08-14 | due-trials |
| Reported results | 2015-003148-38 | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in... | 2018-06-11 | due-trials |
| Reported results | 2015-003360-37 | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) | 2019-08-12 | due-trials |
| Reported results | 2015-003529-33 | A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impa... | 2017-10-24 | due-trials |
| Reported results | 2015-003622-13 | BI 655066 (risankinumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis-2 (UltIMMa-2) Studio randomizz... | 2017-09-04 | due-trials |
| Reported results | 2015-003623-65 | 655066/ABBV-006 (risankizumab)versus adalimumab in a randomized, double blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatment and... | 2017-08-27 | due-trials |
| Reported results | 2015-003625-34 | A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 / ABBV-066 / risankiumab in patients with active psoriatic arthritis | 2017-08-31 | due-trials |
| Completed, but no date, and reported results | 2015-003718-25 | A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated locally advanced or metastatic colorectal ca... | bad-data | |
| Reported results | 2015-003879-29 | A 4-week, randomised, double-blind, parallel group study to evaluate the efficacy and safety of tiotropium + olodaterol fixed dose combination (5/5 µg) delivered by the Respimat® inhaler versus the fr... | 2017-03-13 | due-trials |
| Reported results | 2015-004412-38 | RE-SPECT CVT: a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients with c... | 2018-06-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-004625-14 | Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy reg... | 2016-03-28 | bad-data |
| Reported results | 2015-005079-26 | ELUXA 2: An international, randomised, multi-centre, active controlled, open-label Phase III study evaluating the efficacy of BI 1482694 versus standard platinum doublet chemotherapy in patients with ... | 2016-08-11 | due-trials |
| Reported results | 2015-005427-10 | LUX-Bladder 1: Phase II open label single arm exploratory trial of oral afatinib monotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with genetic al... | 2019-09-02 | due-trials |
| Reported results | 2015-005438-24 | A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p... | 2019-11-19 | due-trials |
| Reported results | 2016-000285-28 | A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients wit... | 2020-01-29 | due-trials |
| Reported results | 2016-000499-83 | A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally a... | 2019-06-14 | due-trials |
| Reported results | 2016-000612-14 | BI 695501 versus Humira® in patients with active Crohn’s disease: a randomized, double-blind, multicenter, parallel group, exploratory trial comparing efficacy, endoscopic improvement, safety, and imm... | 2019-05-13 | due-trials |
| Reported results | 2016-000613-79 | Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparato... | 2018-01-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-000669-21 | A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ext... | 2023-05-31 | bad-data |
| Reported results | 2016-002254-20 | VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm, mu... | 2019-04-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002278-11 | A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fractio... | 2021-04-26 | bad-data |
| Reported results | 2016-002280-34 | A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction ... | 2020-05-28 | due-trials |
| Reported results | 2016-002971-91 | A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ... | 2020-05-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003403-66 | An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD) | 2023-01-25 | bad-data |
| Reported results | 2016-004572-21 | Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy | 2020-09-16 | due-trials |
| Reported results | 2016-004573-40 | Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics and pharmacogenomics of multiple intravenous doses of BI 655... | 2018-11-14 | due-trials |
| Other | 2016-004973-42 | A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early interven... | not-yet-due | |
| Reported results | 2016-005042-37 | A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung | 2020-01-13 | due-trials |
| Reported results | 2017-000100-20 | Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment with BI 655130 in Patients with Active Ulcerative Colitis (UC) | 2019-10-29 | due-trials |
| Reported results | 2017-000376-28 | A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients with... | 2020-05-28 | due-trials |
| Exempt | 2017-001221-40 | Safety, tolerability and pharmacodynamics of single rising intravitreal and multiple rising intravitreal doses of BI 836880 in patients with wAMD (open label, non-randomized, uncontrolled). | 2023-11-01 | not-yet-due |
| Completed, but no date, and reported results Terminated | 2017-002369-23 | A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive therap... | bad-data | |
| Ongoing, reported early | 2017-002971-24 | A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease | not-yet-due | |
| Reported results | 2017-003090-34 | Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease | 2022-07-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-003101-17 | An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out... | 2021-07-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-003131-11 | XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i... | 2022-04-26 | bad-data |
| Reported results | 2017-004072-59 | A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie... | 2019-10-09 | due-trials |
| Reported results | 2017-004073-14 | A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie... | 2019-10-07 | due-trials |
| Reported results | 2017-004230-28 | A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act... | 2020-05-18 | due-trials |
| Reported results | 2017-004231-37 | Effisayil™ 1:Multi-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP)... | 2021-01-05 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-000334-35 | An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials | 2023-05-03 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-000525-32 | An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) | 2022-08-30 | bad-data |
| Other | 2018-002344-81 | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advan... | not-yet-due | |
| Other | 2018-002740-82 | A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week t... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-003078-28 | Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to sev... | 2021-07-28 | bad-data |
| Ongoing | 2018-003080-56 | An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP) | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-003081-14 | Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ... | 2022-12-20 | bad-data |
| Reported results Terminated | 2018-003487-31 | Phase II long-term extension study to assess the safety, tolerability, and efficacy of BI 730357 in patients with moderate-to-severe plaque psoriasis | 2021-07-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-004530-14 | A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted... | 2022-05-24 | bad-data |
| Reported results Terminated | 2019-000261-21 | A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to s... | 2020-04-28 | due-trials |
| Listed as ongoing, but also has a completion date | 2019-001037-13 | A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in ... | 2023-11-05 | bad-data |
| Reported results | 2019-001673-93 | An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s disease who have completed previous spesolimab trials | 2022-09-23 | due-trials |
| Reported results Terminated | 2019-001684-77 | A 12-weeks Phase II, randomized, double-blind, placebocontrolled, parallel-group, proof-of-concept trial of BI 730357 in patients with active ankylosing spondylitis A BI 730357 vizsgálati gyógyszer... | 2021-08-18 | due-trials |
| Reported results | 2019-001719-21 | A randomized, double blind, placebo-controlled, multi-center, parallel group study to compare the efficacy of inhaled tiotropium + olodaterol, fixed dose combination (5μg/5μg) vs. placebo delivered by... | 2020-09-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-002390-60 | A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mell... | 2021-11-05 | bad-data |
| Reported results | 2019-002946-19 | A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia... | 2021-06-02 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-003182-17 | A Phase II, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging, proof-of-concept trial of BI 730357 given for 12 weeks in patients with active psoriatic arthritis | 2021-07-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-004167-45 | A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally. | 2021-10-15 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-004264-21 | A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial with a quetiapine arm to evaluate the efficacy, tolerability and safety of oral BI 135... | 2024-02-02 | bad-data |
| Reported results | 2019-004749-33 | An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal | 2020-11-19 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-000078-12 | A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit... | 2023-01-25 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-000189-41 | An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials | 2023-06-07 | bad-data |
| Ongoing | 2020-000384-23 | A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-002479-37 | A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight | 2022-10-07 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-002723-11 | Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of ... | 2023-12-21 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-002913-16 | The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of dai... | 2022-07-25 | bad-data |
| Reported results | 2020-002929-28 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in pati... | 2022-12-27 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-002930-33 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in pati... | 2023-09-21 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2020-003672-40 | Randomized, double-blind, placebo-controlled, study of spesolimab in patients with moderate or severe hidradenitis suppurativa | 2022-04-27 | bad-data |
| Ongoing | 2020-003726-23 | A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (C... | not-yet-due | |
| Ongoing | 2020-003744-84 | A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (... | not-yet-due | |
| Ongoing | 2020-003745-11 | An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) | not-yet-due | |
| Ongoing | 2020-003760-11 | A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with sch... | not-yet-due | |
| Ongoing | 2020-004527-16 | A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with C... | not-yet-due | |
| Ongoing | 2020-005554-23 | A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON) | not-yet-due | |
| Ongoing | 2020-005587-55 | An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS) | not-yet-due | |
| Reported results | 2020-005588-29 | A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomati... | 2021-10-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-005770-99 | Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr... | 2022-05-31 | bad-data |
| Completed, but no date, and reported results Terminated | 2021-000408-39 | A Phase III randomized, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for post-exposure prevention of SARS-CoV-2 i... | bad-data | |
| Ongoing | 2021-001285-38 | Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-001434-19 | Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl... | 2023-07-10 | bad-data |
| Ongoing | 2021-002392-20 | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-003154-23 | A Phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in pat... | 2023-11-20 | bad-data |
| Ongoing | 2021-003304-41 | A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis | not-yet-due | |
| Other | 2021-005171-40 | Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with ... | not-yet-due | |
| Ongoing | 2022-001091-34 | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | not-yet-due | |
| Ongoing | 2022-001134-11 | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | not-yet-due | |
| Ongoing | 2022-001500-18 | Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenoc... | not-yet-due |